Loading stock analysis…
Evidence Synthesis
Last synthesized: 20 Oct 2026, 10:23
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence velocity
Rate-of-change signals for this ticker unlock with Pro — or view flagship demos TCS / RELIANCE.
Evidence Synthesis
SKYBIOTECH Sees Gross Margin Accelerate to 45.92% in Quarterly Update, Despite Declining Marginal Operating Leverage to -102.89%.
Daily Volume Drops Sharply to , Following a Quarterly Rebound in Revenue Growth to . Close Price Remains Flat at .
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 45.92 % | -102.89 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | -102.89 % | -30.2 | ▼ |
| REVENUE_GROWTH_YOY | -77.1 % | — | - |
| PRICE_CHANGE_PERCENT | 0 % | — | - |
| DAILY_VOLUME | 9 shares | 188 | ▼ |
| CLOSE_PRICE | 117 INR | 117 | - |
Cite this
Source: Samhati evidence synthesis for SKYBIOTECH (2026-10-20). Observation: SKYBIOTECH Sees Gross Margin Accelerate to 45.92% in Quarterly Update, Despite Declining Marginal Operating Leverage to -102.89%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/skybiotech
Filing step-changes